Walk into almost any large healthcare or life sciences organization and you will find at least one AI project that delivered. It routed the right case to the right specialist, drafted the first version of a report, flagged an anomaly a human might have missed, or handed a stretched team hours back in the week. The proof of concept did its job.
Then it stopped there. The result that landed in one ward, one trial, or one analytics team rarely becomes the way the whole organization runs. Plenty of teams have a single AI win they can point to. Very few have turned that win into something consistent, trusted, and enterprise wide.
One important bottleneck is the data underneath the model, and the plumbing that moves it between systems. A pilot can succeed on a hand-assembled clean dataset, then struggle when that setup meets the rest of the estate. That does not make model performance, clinical validation, user adoption, or workflow design optional. Scaling requires the data path and the intended use to be evaluated together.
What the jump from pilot to production really demands
Scaling is not running the same pilot in more departments. It is the shift from a single, supervised proof of concept to a capability that runs reliably across many workflows, many sites, and many data sources without a specialist babysitting it. That means the same model has to receive data in the same shape whether it comes from an imaging archive, a lab system, a clinical trial database, or a commercial dataset bought from a third party.
Put differently, a pilot proves the model can be useful once. Scaling proves the organization can feed that model correctly, repeatedly, and auditably, at volume, while the underlying systems keep changing. Those are different problems. The first is a data science problem. The second is a data engineering and architecture problem, and it is the one that quietly decides whether the investment ever pays off.
Why most pilots stall before they scale
Gartner’s July 2024 forecast anticipated at least 30 percent of generative AI projects being abandoned after proof of concept by end-2025, citing several causes including data quality. BCG’s 2025 enterprise-AI research reported that around 60 percent of companies were obtaining little material value. These concern different populations and measures; neither is a clinical-pilot failure rate.
The research supports treating integration and governance as important parts of scaling, not as the only causes of failure. The OECD’s 2026 health-AI report identifies fragmented data, policy, workforce, and governance barriers. A 2025 hospital-platform systematic review examined 29 studies in 11 countries and found uneven maturity across infrastructure, data, algorithms, applications, and security/compliance. Its evidence base was varied, so it does not establish a universal recipe or show that model evaluation can be skipped.
In other words, the thing that makes a pilot easy is exactly the thing that makes scaling hard. A pilot lets you cheat. You can curate a clean slice of data by hand. Production does not let you cheat, because the data never stops arriving and it never arrives clean.
The integration layer is the real bottleneck
When teams say "we have a data problem," they usually mean three separate problems wearing one coat.
The first is fragmentation. Critical information sits in systems that were never designed to talk to each other: imaging archives, laboratory systems, electronic health records from different vendors, trial databases, and an expanding set of device and wearable streams. The systematic review of hospital AI architecture describes this directly, citing siloed imaging and lab systems and inconsistent adoption of interoperability standards such as HL7 FHIR across EHR vendors as a primary barrier. Standards exist. Consistent adoption of them does not.
The second is semantic mismatch. Even when two systems can exchange a file, the same clinical or operational concept is often coded differently in each. Until those meanings are reconciled, you do not have integrated data. You have two incompatible spreadsheets in the same folder.
The third is the human cost of papering over the first two. Cleaning and preparing data remains one of the most labor-intensive parts of any data science effort, and in healthcare it is heavier still because the data is sensitive, irregular, and high stakes. When that work is done manually for every pilot, it does not compound. Each new use case starts the cleaning from scratch, which is the opposite of scaling.
The takeaway is blunt: the gating step for scaling AI in healthcare is making complex clinical and operational data usable across systems. Reusable integration reduces repeated preparation work, but each deployment still needs validation for its population, workflow, permissions, and intended use. Buying a different model does not by itself resolve inconsistent source data.
What good looks like in practice
A practical implementation plan connects four building blocks. The sequence depends on existing systems and the use case, and work on the model and its validation can proceed alongside the foundation.
They build a unified data layer first, so that information from many source systems lands in one governed place in a consistent shape. They build the pipelines that move and reshape that data automatically, so preparation stops being a manual ritual repeated per project and becomes infrastructure that runs on its own. They build a cloud architecture underneath that can grow with demand and separate environments cleanly, so a model in production is not sharing fragile resources with a half-finished experiment. And only then do they put an AI usability layer on top, the part that lets clinicians, analysts, and operational staff actually ask questions of the data without writing code or waiting in a queue.
These layers need to connect. Starting with a visible AI interface while ignoring ingestion, access, quality, and operational isolation can leave a pilot with no reliable production path. Improving the foundation gives the team a reusable base; it does not remove the need to evaluate the model and the workflow.
Why life sciences feels this hardest
Every industry has data sprawl. Life sciences has data sprawl plus three multipliers.
The data volumes are large and growing, spanning trials, commercial datasets, real-world evidence, and device streams. The work is multi-country, which means the same dataset has to be reconciled across different national systems and conventions. And the environment is regulated, so the data layer cannot be a black box. It has to be traceable, governed, and audit-ready by default, with clear lineage from source to output. A consumer tech company can ship a model that is roughly right. A regulated life sciences organization has to be able to show its work.
This is why the integration layer is not a "nice to have" in this sector. It can be a critical prerequisite for cross-system AI workflows. The organizations that treat the data foundation as the project, rather than as a chore to get past on the way to the model, are the ones quietly pulling ahead.
Common signs your environment is not ready to scale
A quick diagnostic. If several of these are true, the next model purchase will not fix it.
A new AI use case still requires weeks of manual data wrangling before it can begin. The same dataset is described differently in two systems and nobody owns the reconciliation. Your successful pilots have not spread beyond the team that built them. Moving to production means re-engineering the data flow from scratch each time. Nobody can produce a clean lineage of where a given number came from. And the people closest to the data spend more time preparing it than analyzing it.
None of these are model problems. All of them are foundation problems, and all of them are fixable.
Where the business case shows up
This is not theoretical. The pattern repeats across the data engineering work we see in life sciences.
In one engagement, a market access analytics platform built for a large research organization unified more than 50 national datasets into a single governed layer, served over 1,000 users across more than 15 countries, and cut manual data preparation by around 60 percent. The model layer was not the hard part. The integration layer was, and once it existed the analytics scaled to a global user base instead of staying trapped in one team.
In another, a domain-specific AI agent let a life sciences data team query their data in plain language across more than 250 curated fields. Queries ran about 35 percent faster and the volume of data people could actually reach grew roughly tenfold. The unlock was not a cleverer model. It was that the data beneath it had been organized and governed so the model could be trusted to answer.
Both examples show operational gains from a governed data foundation. The first is a market access analytics platform; the second is an AI query capability. Neither is evidence that a clinical model has been validated or that every deployment will achieve the same results.
How to Start Scaling Healthcare AI
If your AI pilots are working but not spreading, the problem is probably one layer below where you have been looking. That is the layer DataDrill is built for. We work as an embedded data engineering partner for life sciences organizations, focused on exactly the four building blocks above: unifying fragmented data, automating the pipelines that prepare it, building cloud architecture that scales in regulated environments, and putting a usable AI layer on top once the foundation can support it. We tend to start small and fast, with a tightly scoped pilot of a few weeks against one real bottleneck, so the value is visible before anyone commits to a larger build. The goal is not to add another tool to the stack. It is to give a selected AI workflow a dependable data path and measurable acceptance criteria before expanding it.
Final thought
The hard part of AI in healthcare was never teaching the model to be useful once. It is building the data foundation that lets it be useful everywhere, every day, for everyone who needs it.